Durect (DRRX) Gross Profit Margin starting from the second quarter 2025 to second quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Durect Corp  (NASDAQ: DRRX)


Durect's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DRRX Gross Profit Margin (Jun 30 2025)
Q2 		(Mar 31 2025)
Q1 		(Dec 31 2024)
Q4 		(Sep 30 2024)
Q3 		(Jun 30 2024)
Q2
Y / Y Revenue Change -79.41 %
Seq. Revenue Change 39.25 %
Revenue In Millions $0.45
Gross Profit Margin 98.43 %
Gross Profit Margin Total Ranking # 70
Gross Profit In Millions $0.44
Y / Y Gross Profit Change -75.76 %
Seq. Gross Profit Change -


Commenting Second Quarter 2025 Gross Profit Margin
Durect Corp achieved Gross Profit of $0 millions compare to Gross Loss of $0.00 millions recorded in the previous quarter. Revenue increased by 39.25 % Company accomplished above average Gross Profit Margin with 98.43 % a new company high.


Observing second quarter 2025 results within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 70.
Learn about Gross Margin
DRRX's Gross Profit Margin second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 4
Healthcare Sector # 10
Overall # 69

Gross Profit Margin Statistics
High Average Low
98.43 % 77.42 % 41.76 %
(Jun 30 2025)   (Sep 30 2016)


DRRX Gross Income Trends • More of DRRX's Profitabilty Ratios • DRRX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
DRRX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
DRRX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for DRRX's Competitors
Gross Profit Margin Profit Margin for Durect's Suppliers
Gross Profit Margin Profit Margin for DRRX's Customers

You may also want to know
DRRX's Annual Growth Rates DRRX's Profitability Ratios DRRX's Asset Turnover Ratio DRRX's Dividend Growth
DRRX's Roe DRRX's Valuation Ratios DRRX's Financial Strength Ratios DRRX's Gross Profit Growth
DRRX's Roa DRRX's Inventory Turnover Ratio DRRX's Growth Rates DRRX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2025 MRQ Gross ProfitJun 30 2025 MRQ Revenue
Zai Lab Limited  99.80 %$ 109.760  Millions$ 109.977  Millions
Ptc Therapeutics inc   99.55 %$ 178.075  Millions$ 178.875  Millions
Travere Therapeutics Inc   98.67 %$ 112.928  Millions$ 114.449  Millions
Durect Corp  98.43 %$ 0.440  Millions$ 0.447  Millions
Ovid Therapeutics Inc   98.42 %$ 6.173  Millions$ 6.272  Millions
Corcept Therapeutics Inc  98.23 %$ 190.997  Millions$ 194.430  Millions
Adc Therapeutics Sa  97.93 %$ 18.449  Millions$ 18.839  Millions
Liquidia Corporation  97.68 %$ 8.632  Millions$ 8.837  Millions
Karyopharm Therapeutics Inc   97.23 %$ 36.878  Millions$ 37.929  Millions
Bridgebio Pharma Inc   96.70 %$ 106.912  Millions$ 110.565  Millions
Gyre Therapeutics Inc   95.70 %$ 25.620  Millions$ 26.771  Millions
Rigel Pharmaceuticals Inc  95.57 %$ 97.181  Millions$ 101.685  Millions
Cormedix Inc   95.31 %$ 37.874  Millions$ 39.737  Millions
Vanda Pharmaceuticals Inc   94.80 %$ 49.854  Millions$ 52.590  Millions
Emmaus Life Sciences Inc   94.68 %$ 2.667  Millions$ 2.817  Millions
Verastem Inc   94.01 %$ 2.009  Millions$ 2.137  Millions
Kyntra Bio Inc   93.69 %$ 1.263  Millions$ 1.348  Millions
Regeneron Pharmaceuticals Inc   92.50 %$ 3,400.000  Millions$ 3,675.600  Millions
Acadia Pharmaceuticals Inc   92.16 %$ 243.832  Millions$ 264.566  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Avadel Pharmaceuticals Plc  91.15 %$ 61.763  Millions$ 67.763  Millions
Axsome Therapeutics Inc   91.04 %$ 136.594  Millions$ 150.042  Millions
Amicus Therapeutics inc   90.29 %$ 139.471  Millions$ 154.471  Millions
Aurinia Pharmaceuticals Inc   89.84 %$ 62.893  Millions$ 70.008  Millions
Supernus Pharmaceuticals inc   89.83 %$ 148.626  Millions$ 165.453  Millions
Y mabs Therapeutics inc   89.40 %$ 16.863  Millions$ 18.863  Millions
Innoviva Inc   89.26 %$ 83.146  Millions$ 93.146  Millions
United Therapeutics Corporation  89.03 %$ 711.000  Millions$ 798.600  Millions
Rhythm Pharmaceuticals Inc   88.57 %$ 42.959  Millions$ 48.502  Millions
One World Products Inc   88.30 %$ 0.000  Millions$ 0.000  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.